JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

RCC-Ma loss predicts poor survival and metastatic risk in clear cell renal cell carcinoma

  • 0Institute of Pathology, University Medical Center Mainz, Langenbeckstr. 1, Mainz 55131, Germany; Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt of the Goethe University Frankfurt, Theodor-Stern-Kai 7, Frankfurt am Main 60590, Germany.
Pathology, Research and Practice +

|

March 23, 2025

|

March 23, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Loss of RCC-Ma expression in clear cell renal cell carcinoma (ccRCC) is a significant predictor of poor survival and increased metastasis risk. This finding aids in refining prognostic models for ccRCC patients.

Area Of Science

  • Oncology
  • Pathology
  • Biomarker Discovery

Background

  • Accurate classification of renal cell carcinoma (RCC) subtypes is crucial for prognosis and treatment.
  • Clear cell renal cell carcinoma (ccRCC) exhibits complex immunoprofiles challenging standard diagnostic paradigms.
  • Investigating immunohistochemical heterogeneity in ccRCC is essential for improved patient stratification.

Purpose Of The Study

  • To analyze immunohistochemical staining patterns in ccRCC.
  • To determine the prognostic value of specific biomarkers in ccRCC.
  • To identify reliable indicators for patient survival and metastatic risk.

Main Methods

  • A cohort of 727 ccRCC patients treated surgically between 1995-2006 was analyzed.
  • Immunohistochemical staining was performed on tissue microarrays for vimentin, CAIX, CD10, RCC-Ma, AMACR, CK7, and CD117.
  • Expression levels were semiquantitatively scored and correlated with clinicopathological features and patient survival, stratified by the Leibovich Risk Score (LRS).

Main Results

  • Loss of RCC-Ma expression independently predicted disease-specific survival (p=0.01).
  • Reduced RCC-Ma was associated with higher metastasis risk in the intermediate LRS group.
  • Loss of RCC-Ma correlated with aggressive features like higher tumor grade, stage, metastasis, and necrosis.

Conclusions

  • RCC-Ma serves as a valuable prognostic biomarker for risk stratification in ccRCC.
  • Loss of RCC-Ma predicts poor survival and increased metastatic potential.
  • This study provides a valuable reference for understanding the natural course of ccRCC, aiding future research including targeted therapies.

Keywords:

Related Concept Videos

The Retinoblastoma Gene 01:20

4.0K

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

Cancer Survival Analysis 01:21

313

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

mTOR Signaling and Cancer Progression 03:03

3.7K

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...